Medically reviewed by Jacque Lovely, RN, MScN, MBA | Head of Western Operations at ATMA CENA
Becoming a psychedelic therapist in Canada starts with a regulated clinical credential — not a training certificate. From there the route depends on your profession: register with your college, build clinical experience, choose a pathway, complete training that includes a supervised practicum, and join a setting where you can practise. This guide walks each step in order.
Key takeaways
- You cannot practise as a “psychedelic therapist” without first holding a regulated clinical credential. The credential is the gate; the training certificate is not.
- The route differs by profession. Physicians and nurse practitioners can prescribe and submit Special Access Program (SAP) applications; psychotherapists, psychologists, and counsellors deliver the psychotherapy components within a supervised team.
- Ketamine-assisted therapy is the most accessible context today. Ketamine is an approved medicine prescribed off-label — no SAP application required. Psilocybin and MDMA require Health Canada SAP authorization on a case-by-case basis.
- Training is built on a supervised practicum, not online content alone. Health Canada’s risk-management expectations point to supervised, experiential components.
- Scope and eligibility depend on your province. Alberta restricts psychedelic treatment providers to members of six named regulated colleges. CRPO in Ontario is still developing guidance, with no finalized standard as of May 2026.
If you are weighing whether this path fits your credential, explore ATMA CENA’s training pathways or book a free information call.
What Does a Psychedelic Therapist Do in Canada?
A psychedelic therapist in Canada is a regulated clinical practitioner who has completed specialized training in psychedelic-assisted therapy (PAT) and delivers preparation, in-session support, and integration psychotherapy as part of a multidisciplinary team. Only physicians and nurse practitioners prescribe the medicine and submit Special Access Program applications. Psychotherapists, psychologists, counsellors, social workers, and nurses contribute the psychotherapy and support components within their provincial scope.
There is no separate, unregulated “facilitator” licence in Canada the way there is in Oregon or Colorado. The therapeutic relationship is part of the clinical work — a published competency framework names empathetic abiding presence and trust enhancement among the six core competencies of psychedelic therapists (Phelps, 2017).
The role is distinct from two others people often confuse it with. A prescriber is a physician or nurse practitioner who holds the medication authority. An integration coach is typically an unregulated practitioner who offers post-experience support outside a SAP-authorized clinical context and cannot serve as the therapist of record on a clinical team.
If you are not yet a regulated mental-health professional, your path begins with earning a clinical credential first. If you are already registered, it begins with confirming what your scope allows and choosing the right training pathway.
Which Substances Can You Work With, and Who Prescribes?
Canadian access to psychedelics in clinical practice falls into three tiers. Knowing them up front explains why the route differs by profession and why ketamine is usually the faster entry point.
| Substance | Status in clinical practice | Who holds the medication authority |
|---|---|---|
| Ketamine | Approved anaesthetic; psychiatric use is off-label under provincial-college rules | Physicians and nurse practitioners with controlled-substance authority |
| Psilocybin | Restricted drug; access via Health Canada SAP only, case by case | Physicians and nurse practitioners submit the SAP application |
| MDMA | Restricted drug; access via Health Canada SAP only, case by case | Physicians and nurse practitioners submit the SAP application |
| LSD, mescaline, DMT, ibogaine, 5-MeO-DMT | Access only through authorized clinical trials | Research investigators |
Ketamine-assisted therapy is the only context available for routine clinical practice without case-by-case federal authorization. The Psychedelic Association of Canada documented approximately half as many SAP approvals year over year as of September 2025, so a practice built primarily on psilocybin or MDMA access faces longer and less predictable timelines than one built on ketamine.
The Steps to Become a Psychedelic Therapist in Canada
The sequence below is the same for everyone in its shape; the detail inside each step changes with your profession.
Step 1: Register With Your Professional College
The first step is holding a regulated clinical credential in your province. Becoming a psychedelic therapist is not a standalone qualification you earn through a course — it is an added competency on top of an existing licence to practise.
Physicians and nurse practitioners register with their provincial medical or nursing college. Psychologists register with the provincial psychology college (CAP, CHCPBC, CPBAO, PAM, or OPQ). Registered Psychotherapists register with CRPO in Ontario; psychotherapy permit-holders register with OPQ in Quebec. Counsellors hold designations such as CCC (CCPA) or RCC (BCACC).
If you are entering the field new, choosing the credential at the front of the pipeline matters. Master’s-level psychotherapy registration is a faster route to independent practice than a doctoral psychology degree, while a doctoral psychologist’s scope is broader and more portable across provinces.
Pro tip: Restricted titles are enforced. “Psychologist” is restricted in every province to college registrants. “Registered Psychotherapist” is restricted in Ontario to CRPO. “Psychothérapeute” is restricted in Quebec to OPQ permit holders. Use only the title your registration entitles you to.
Step 2: Build Relevant Clinical Experience
Most substantive PAT training expects one to several years of post-registration clinical experience before you enrol, with the exact expectation rising for prescribing roles. The first published therapist-training cohort averaged decades of post-qualification experience (Tai et al., 2021) — programs select for established clinicians rather than new graduates.
What counts as qualifying experience is trauma-informed and relational practice: work with PTSD, treatment-resistant depression, mood and anxiety disorders, substance use, or end-of-life distress, using approaches such as EMDR, somatic therapy, internal family systems, CBT, or DBT. Across a systematic review of 52 trials, the quality of the psychedelic experience and the therapeutic alliance predicted outcomes (Breeksema et al., 2022), so the relational skills you already use transfer directly into PAT.
Step 3: Choose Your Pathway by Profession
PAT training at ATMA CENA splits into three pathway types. The Prescriber Pathway is for physicians and nurse practitioners, who learn medication selection, screening, dosing oversight, and SAP application authorship. The Clinical Pathway is for psychotherapists, psychologists, and counsellors, who learn to deliver preparation, in-session support, and integration psychotherapy within a supervised team. The Integrative Pathway suits clinicians whose role is preparation and integration only, without dosing-day involvement.
| Your profession | Can prescribe / submit SAP? | Primary pathway | What you deliver |
|---|---|---|---|
| Physician (MD), nurse practitioner | Yes | Prescriber | Screening, prescribing, dosing oversight, SAP applications |
| Registered Psychotherapist (CRPO), OPQ permit-holder | No | Clinical | Preparation, in-session therapeutic guide, integration |
| Registered Psychologist | No | Clinical | Assessment, therapy delivery, outcome measurement |
| Counsellor (CCC, RCC) | No | Clinical (with scope caveat) or Integrative | Preparation and integration; team-based in-session support |
For the full decision logic, see Which Psychedelic Therapy Training Pathway Is Right for Me?
Step 4: Complete Training, Including a Supervised Practicum
Online didactic learning is the foundation, not the finish line. Health Canada’s December 2022 risk-management expectations state that therapists should be properly trained on evidence-informed protocols and that during dosing there should be a minimum of two therapists present. In the first published evaluation of a psilocybin therapist-training program, trainees rated supervised clinical engagement as the most beneficial and the most challenging part of the training (Tai et al., 2021).
ATMA CENA’s training is pathway-based. Every pathway begins with the Foundations course.
| Course | Hours | CE Credits | Tuition (CAD) | Format |
|---|---|---|---|---|
| PAT Foundations | 14 hrs | 14 | $800 | Online (async) |
| Applied Clinical Practice in Psychedelic Therapy | 46 hrs | 46 | $4,200 | Online + practicum |
| Prescribing & Oversight in PAT | 40 hrs | 40 | $4,000 | Hybrid |
| Advanced Safety & Support Practices in PAT | 38 hrs | 38 | $3,500 | Hybrid |
| Supervised Learning Lab | 8 hrs | 8 | $1,000 | Small-group cohort (live) |
| KAT Immersive Experience (optional) | 3 days | Pending CE approval | $2,400 | In-person, Calgary only |
Pathway bundles (10% discount applied): Clinical Pathway $5,400 | Prescriber Pathway $4,320 | Integrative Pathway $3,870. Payment plans available: 2-month and 3-month options.
For a full cost breakdown, see Psychedelic Therapy Training Cost in Canada.
Step 5: Secure a Setting Where You Can Practise
Completing training does not authorize you to administer a psychedelic — that authority sits with prescribers. What completion establishes is the competence to deliver your part of the work within an authorized setting. There are three common routes into practice:
Ketamine-assisted therapy — the fastest route. Confirm your scope with your provincial college, then join or build a multidisciplinary team where a prescribing physician or nurse practitioner holds the medication. Provincial rules govern the setup:
- Alberta (CPSA): psychedelic-assisted psychotherapy must occur in a CPSA-accredited facility under psychiatrist or physician-in-consultation-with-psychiatrist oversight (March 2026 guidance).
- British Columbia (CPSBC): non-IV ketamine governed by CPSBC interim guidance, Version 1.3, August 2025.
- Manitoba (CPSM): CPSM January 2026 guidance sets prescriber requirements.
- Ontario (CPSO): no ketamine-specific policy as of May 2026 — off-label prescribing falls under general standards.
Psilocybin or MDMA via SAP. The prescribing physician or nurse practitioner submits the SAP application for an eligible patient. You serve as the preparation or integration therapist, or as the non-prescribing therapist in the two-therapist dosing model. Treat SAP as a case-by-case pathway, not a predictable one.
A clinic network that handles the infrastructure. ATMA CENA’s CoCare program lets clinicians who have completed the Clinical Pathway deliver preparation and integration psychotherapy with their own clients while ATMA CENA’s clinical infrastructure handles prescribing, dosing-day oversight, and facility compliance. Note: the current per-province CoCare eligibility map by designation is pending confirmation — confirm at intake.
Step 6: Maintain Competence and Continuing Education
PAT is a fast-moving field, and competence is something you maintain rather than complete. Plan for case consultation, peer supervision, and continuing education that satisfies your college’s requirements. Many clinicians keep building across substances and integration frameworks over years rather than weeks.
How Long Does It Take?
The timeline depends almost entirely on whether you are already licensed and which substance context you target.
| Starting point | Realistic time to first supervised PAT work |
|---|---|
| Licensed therapist, ketamine-assisted therapy | A few months of PAT training plus team setup |
| Licensed therapist, psilocybin or MDMA via SAP | Longer and less predictable under current SAP conditions |
| Physician or nurse practitioner, ketamine prescribing | Short, after prescriber training |
| New entrant (undergraduate through to registration) | Several years through the full pipeline before PAT training |
These are planning estimates, not guarantees — your actual timeline depends on your credential, your province, and the setting you join.
Frequently Asked Questions
Do I need to be a licensed therapist first?
Yes, for any clinical PAT role. The credential is the gate. To serve as a therapist within a SAP-authorized program or a clinical trial, you must hold a regulated clinical registration in your province. Unregulated practitioners can offer integration coaching or wellness preparation outside a SAP context, but cannot act as the therapist of record on a PAT team.
Is psychedelic therapy legal in Canada?
Ketamine-assisted therapy is legal — ketamine is an approved anaesthetic, and psychiatric use is off-label under provincial-college rules. Psilocybin and MDMA are restricted drugs accessible only through Health Canada’s Special Access Program on a case-by-case basis, and SAP approval is not guaranteed. All other psychedelics are limited to authorized clinical trials.
Can I become a psychedelic therapist without a master’s degree?
Generally no for clinical roles. Master’s-level training is the floor for most provincial psychotherapy and counselling registrations, and doctoral training is the standard for the full “Psychologist” title in most provinces. Confirm the specific requirement with the college you intend to register with.
Is online training enough?
No. Online didactic content is foundational but not sufficient on its own. Health Canada’s risk-management expectations and the published training literature both point to supervised and experiential components. Hybrid programs that combine online learning with a supervised practicum are the credible standard.
What is the difference between a psychedelic therapist and a facilitator?
“Therapist” implies a regulated clinical credential and clinical scope. “Facilitator” is a term used in jurisdictions with non-clinical licensing structures, such as Oregon and Colorado, and does not exist as a regulated category in Canada. The therapy role sits with regulated professionals.
Which province is best to train and practise in?
It depends on your credential and target patients. Alberta has the most developed provincial framework, including the CAP June 2025 psychedelic-assisted psychotherapy practice guideline and CPSA facility accreditation. Ontario and British Columbia have higher private-clinic density. CRPO in Ontario is still developing PAP guidance, with no finalized standard as of May 2026, so Ontario psychotherapists should document their competency development carefully.
How do I start if I am already licensed?
Confirm what your provincial scope allows, choose the pathway that matches your profession, and begin with the Foundations course before moving into your pathway-specific courses and supervised practicum. An advisor call can map the sequence to your specific credential.
Compliance Disclaimer
Ketamine is approved by Health Canada as an anaesthetic. Use for depression, anxiety, PTSD, and other mental-health indications is off-label, regulated by provincial medical regulators — for example, CPSA in Alberta, CPSM in Manitoba, and CPSO in Ontario.
Psilocybin and MDMA are restricted drugs under Canada’s Controlled Drugs and Substances Act. Patient access to psilocybin- or MDMA-assisted therapy is available only through Health Canada’s Special Access Program (SAP). SAP approval is granted on a case-by-case basis and is not guaranteed. Psilocybin SAP is primarily approved for adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness. MDMA SAP is primarily approved for adults with PTSD. Completion of a training program does not authorize anyone to administer psilocybin or MDMA — SAP applications must be submitted by an authorized prescriber.
This article is educational and is not a clinical recommendation for any individual. Practise only within your provincial scope and regulatory framework.
About the Author
Reverdi Darda, CEO & Founder, ATMA CENA
Reverdi Darda, RN is CEO & Founder of ATMA CENA and a Registered Nurse with over three decades of experience in healthcare operations, community engagement, policy development, and strategic planning. A recognized leader in mental health access, Reverdi has dedicated her career to advancing evidence-based treatment models and advocating for policy change that prioritizes effective care. She founded ATMA CENA to expand practitioner and public access to psychedelic-assisted therapy across Canada.
Medically reviewed by Jacque Lovely, RN, MScN, MBA | Head of Western Operations at ATMA CENA
Sources
- Phelps, J. (2017). Developing Guidelines and Competencies for the Training of Psychedelic Therapists. Journal of Humanistic Psychology, 57(5), 450–487.
- Tai, S.J. et al. (2021). Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression. Frontiers in Psychiatry, 12, 586682.
- Breeksema, J.J. et al. (2022). Psychedelic treatments for psychiatric disorders: a systematic review and thematic synthesis of patient experiences in qualitative studies. Frontiers in Psychology.
- Mitchell, J.M. et al. (2021). MDMA-assisted therapy for severe PTSD: Phase 3 MAPP1. Nature Medicine, 27, 1025–1033.
- Mitchell, J.M. et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: Phase 3 MAPP2. Nature Medicine, 29, 2473–2480.
- Health Canada (2022). Notice to stakeholders: Requests to the Special Access Program (SAP) involving psychedelic-assisted psychotherapy.
- Health Canada (2022). Expectations for risk-management measures for clinical trials involving psychedelic-assisted psychotherapy.
- College of Alberta Psychologists (2025). Psychedelic-Assisted Psychotherapy Practice Guideline (June 2025).
- College of Physicians and Surgeons of Alberta (2026). Ketamine Prescribing, Administration and Oversight Expectations (March 2026).
- CPSBC (2025). Interim Guidance: Ketamine Administration via IM/Oral/SL/IN Routes (Version 1.3, August 2025).
- CPSM (2026). Ketamine: What Prescribers and Pharmacists Need to Know (January 2026).
- College of Registered Psychotherapists of Ontario. Psychedelic-Assisted Psychotherapy Resource.
- Psychedelic Association of Canada (2025). Sharp decline in Health Canada SAP approvals (September 2025).
